接受嵌合抗原受体（CAR-T）治疗的患者中，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的严重表现及高死亡率：一项英国国家癌症协作组（NCCP）分析 - Suppr | 超能文献

相似文献

1

Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.接受嵌合抗原受体（CAR-T）治疗的患者中，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的严重表现及高死亡率：一项英国国家癌症协作组（NCCP）分析

Leuk Lymphoma. 2022 Aug;63(8):1980-1984. doi: 10.1080/10428194.2022.2057487. Epub 2022 Apr 28.

2

Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.COVID-19 感染后复发/难治性多发性骨髓瘤患者抗 BCMA CAR T 治疗：1 例报告。

J Med Case Rep. 2021 Feb 19;15(1):90. doi: 10.1186/s13256-020-02598-0.

3

Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.造血干细胞移植和嵌合抗原受体 T 细胞治疗受者对 SARS-CoV-2 疫苗接种的免疫反应。

J Hematol Oncol. 2022 Jun 16;15(1):81. doi: 10.1186/s13045-022-01300-9.

4

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy.与 COVID-19 和嵌合抗原受体 T 细胞疗法引起的细胞因子释放综合征相关的临床特征和危险因素。

Bone Marrow Transplant. 2021 Mar;56(3):570-580. doi: 10.1038/s41409-020-01060-5. Epub 2020 Sep 17.

5

Prolonged SARS-CoV-2 Infection in a CAR T-Cell Therapy Recipient.一名接受嵌合抗原受体 T 细胞疗法（CAR T 细胞疗法）的患者出现了新冠病毒（SARS-CoV-2）的长期感染。

JAMA. 2021 Mar 9;325(10):924. doi: 10.1001/jama.2021.2493.

6

An update on ICU outcomes in patients after CAR T therapy: A four-year tertiary UK centre experience.嵌合抗原受体T细胞（CAR T）疗法后患者重症监护病房（ICU）结局的最新情况：英国一家三级中心的四年经验

J Crit Care. 2024 Apr;80:154511. doi: 10.1016/j.jcrc.2023.154511. Epub 2023 Dec 28.

7

SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments.接受嵌合抗原受体 T 细胞治疗的 B 细胞耗竭患者中针对 SARS-CoV-2 刺突蛋白的 T 细胞反应。

JAMA Oncol. 2022 Jan 1;8(1):164-167. doi: 10.1001/jamaoncol.2021.6030.

8

COVID-19 in patients with cancer: Risks and precautions.癌症患者的 COVID-19：风险与预防措施。

Am J Emerg Med. 2021 Oct;48:357-360. doi: 10.1016/j.ajem.2021.01.067. Epub 2021 Jan 28.

9

CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines .CAR-NK 细胞能有效靶向表达 SARS-CoV-2 刺突蛋白的细胞系。

Front Immunol. 2021 Jul 23;12:652223. doi: 10.3389/fimmu.2021.652223. eCollection 2021.

10

Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection.糖蛋白靶向 CAR-NK 细胞治疗 SARS-CoV-2 感染。

Front Immunol. 2021 Dec 23;12:763460. doi: 10.3389/fimmu.2021.763460. eCollection 2021.

引用本文的文献

1

SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）感染不影响接受嵌合抗原受体（CAR）T细胞疗法治疗的复发/难治性大B细胞淋巴瘤患者的治疗结果。

Ann Hematol. 2025 Jun 4. doi: 10.1007/s00277-025-06425-8.

2

High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.高预处理疾病负担作为大B细胞淋巴瘤CD19嵌合抗原受体T细胞治疗后感染并发症的危险因素。

Hemasphere. 2024 Jan 26;8(1):e29. doi: 10.1002/hem3.29. eCollection 2024 Jan.

3